.
The main examples, as discussed in the Review 1 , are pressure overload-induced HF, ischaemic HF, and diabetes-induced HF (diabetic cardiomyopathy). From a metabolic perspective, these forms of HF differ markedly in that in both pressure overload-induced HF and ischaemic HF, substrate preference shifts towards increased glucose utilization, whereas in diabetic cardiomyopathy, fatty acids become the preferred substrate 3, 4 . In the Review, HF is considered to be caused by pressure overload or ischaemia, whereas diabetic cardiomyopathy is discussed separately, which is confusing. For example, the statement that "The failing heart is characterized by an increase in glucose uptake and glycolytic rates" (page 461) 1 is valid for pressure overload-induced HF and ischaemic HF, not diabetes-induced HF.
Toxic intracellular accumulation of lipid species (lipotoxicity) is mentioned as a contributing cause of HF. However, the contribution of lipotoxicity to the progression of HF is well-known in diabetic HF but has not been established for pressure overload-induced HF 3 . The same applies for the role of decreased insulin sensitivity in developing HF 4 . Moreover, lipotoxicity and insulin resistance are unlikely to be general features of the pressure-overloaded heart.
With respect to targeting substrate metabolism as a treatment option for HF, the hypothesis is discussed that inhibition of fatty acid oxidation might be beneficial because it would induce a shift towards increased utilization of glucose, which has substrate utilization and improve cardiac contractile function 10 . Finally, besides discerning between forms of HF, distinction should also be made between stages of HF development because the type and degree of metabolic adaptation of the heart change during the course of HF progression 7 . Monitoring the cardiac metabolic state is, therefore, not only of interest for early identification of changes in substrate preference but also to predict and assess the effectiveness of treatment.
higher oxygen efficiency than fatty acids. Such intervention is helpful in ischaemic HF but not in pressure overload-induced HF 5, 6 and certainly not in diabetic HF because that would lead to a further mismatch between fatty acid uptake and oxidation, resulting in increased intracellular accumulation of toxic lipid species 5, 7 . The interplay between the intracellular utilization of glucose and of fatty acids for oxidative energy provision (the Randle cycle) is adequately described, but the Review does not mention that a major rate-governing kinetic step in overall myocellular glucose utilization is cardiac glucose uptake 8 , and that in fatty acid utilization it is the fatty acid uptake process (that is, trans-sarcolemmal transport) 9 . Specifically, the relative presence of glucose transporters (GLUT1 and GLUT4) and fatty acid transporters (mainly SR-B2, also known as CD36) in the sarcolemma determines the myocardial utilization of glucose and fatty acids, respectively, and, as a corollary, controls cardiac substrate preference. Therefore, increased sarcolemmal CD36 has been found to be an important early hallmark of the development of diabetic HF 9 . Furthermore, selectively manipulating the recruitment to the sarcolemma of either GLUT4 or CD36 has been reported in experimental animal studies as a suitable approach to rebalance cardiac Reply to 'Metabolic remodelling in heart failure revisited'
Edoardo Bertero and Christoph Maack
We thank Nabben and colleagues for their constructive Correspondence (Metabolic remodelling in heart failure revisited. Nat. Rev We agree with their comments and acknowledge that most of these critical points result from the necessity of giving readers a comprehensive overview of a broad area of cardiovascular research within the limited space of a Review article. Here are our responses to their comments.
We decided to discuss diabetic cardiomyopathy separately from pressure overload-induced and ischaemic heart failure (HF) because they differ completely from a metabolic perspective 2 . Consequently, we refer in the text to the pressure-overloaded or ischaemic heart as the "failing heart", whereas we refer to ventricular dysfunction associated with diabetes mellitus in the absence of hypertension or coronary artery disease as the "diabetic heart" 2, 3 . This distinction is, of course, a simplification, which was intended to make the topic more understandable to readers, and we apologize if it had the opposite effect.
We completely agree with Nabben and colleagues when they state that the role of lipotoxicity and insulin resistance in the development and progression of HF is not fully understood 1 . However, several animal models in which lipotoxicity was induced with genetic manipulation have clearly shown that this process detrimentally affects cardiac function (reviewed previously 4 ), and intramyocardial accumulation of toxic lipid intermediates was observed in patients with HF with or without diabetes 5 . On these grounds, we propose that metabolic derangements in patients with HF might contribute to the progression of cardiac dysfunction; accordingly, throughout our Review, we never present this hypothesis as an established model. of HF, and we referred to the necessity of distinguishing between compensated hypertrophy and end-stage HF in the section on ' Altered substrate metabolism in heart failure' with regard to both fatty acid and glucose utilization. 
